Results 41 to 50 of about 7,827 (211)

How effective are ketamine or esketamine in treatment-resistant depression?

open access: yesEuropean Psychiatry, 2021
Introduction Globally, depression affects millions of individuals. A third of depression patients meet the criteria for treatment-resistant depression (TRD). The N-methyl-D-aspartate receptor antagonist, ketamine, improved depressive symptoms in a span
N. Veluri, Z. Mansuri
doaj   +1 more source

Median effective dose (ED50) of esketamine combined with propofol for children to inhibit response of gastroscope insertion

open access: yesBMC Anesthesiology, 2023
Background Propofol is the most commonly used drug for procedural sedation during gastroscopy. However, independent use of propofol can lead to increased dosage and additional side effects.
Ming Su   +6 more
doaj   +1 more source

Update on Sedation for Upper Gastrointestinal Endoscopy in Japan: Current Evidence on Remimazolam

open access: yesDEN Open, Volume 7, Issue 1, April 2027.
ABSTRACT Sedation is an essential component of upper gastrointestinal endoscopy because it reduces patient discomfort and anxiety while improving patient acceptance and procedural quality. In Japan, benzodiazepines such as midazolam and opioid analgesics have long been widely used in routine clinical practice; however, many of these agents historically
Ryoji Ichijima   +13 more
wiley   +1 more source

Protective effect of esketamine on hepatic ischemia-reperfusion injury [PDF]

open access: yes
Esketamine, as a perioperative sedative and analgesic drug, has been widely used in Europe and America. However, the protective effect of esketamine on the liver during the perioperative period is still in the applicated research stage.
DU Shuyao, LYU Jing, ZHOU Ziyu, FENG Guangwu, LUO Xianghong
core   +1 more source

Efficacy and safety of ketamine for post‐traumatic stress disorder: A systematic review with narrative synthesis and consideration of military and veteran populations

open access: yesPsychiatry and Clinical Neurosciences Reports, Volume 5, Issue 4, December 2026.
Abstract Post‐traumatic stress disorder (PTSD) is a debilitating disorder with limited pharmaceutical treatment options. Ketamine, a noncompetitive N‐methyl‐d‐aspartate (NMDA) receptor antagonist with rapid‐onset effects, has emerged as a potential treatment, particularly for patients who do not respond to first‐line therapies.
Mary Ivasyutyn, Saajan Bhakta
wiley   +1 more source

Comparison of the Effects of Esketamine/Propofol and Sufentanil/Propofol on the Incidence of Intraoperative Hypoxemia during Bronchoscopy: Protocol for a Randomized, Prospective, Parallel-Group Trial

open access: yes, 2022
Background: Propofol, ketamine, and sufentanil are the most commonly used anesthetics during bronchoscopy, alone or in combination, for sedation. Esketamine is an s-enantiomer of ketamine racemate and has both sedative and analgesic effects.
Sun, Yuan   +9 more
core   +1 more source

Effects of Esketamine on Emergence Delirium in Children Undergoing Sevoflurane Anesthesia: A Systematic Review, Meta‐Analysis, and Trial Sequential Analysis

open access: yesPediatric Anesthesia, Volume 36, Issue 11, Page 1361-1374, November 2026.
ABSTRACT Background Emergence delirium is a frequent and distressing postoperative complication in children, particularly following sevoflurane‐based anesthesia. Despite its clinical importance, the optimal preventive strategy remains under investigation.
Munder Lateiresh   +8 more
wiley   +1 more source

A Clinical Rationale for Assessing the Impact of Childhood Sexual Abuse on Adjunctive Subcutaneous Esketamine for Treatment-Resistant Depression

open access: yesFrontiers in Psychiatry, 2021
Background: A history of child sexual abuse (CSA) is related to higher suicide rates and poor treatment outcomes in depressed adult patients. Twenty years after the first study investigating the effects of ketamine/esketamine on depression and suicide ...
Eduardo Jorge Muniz Magalhães   +26 more
doaj   +1 more source

Patients With Atypical Symptoms of Depression Respond Better to Lithium Augmentation Than Patients Without Atypical Symptoms

open access: yesActa Psychiatrica Scandinavica, Volume 154, Issue 5, Page 376-383, November 2026.
ABSTRACT Introduction Understanding the differences in treatment response between subtypes of major depressive disorder (MDD) may help to prevent lengthy trial‐and‐error processes by identifying effective treatment options. The aim of the study was to investigate the impact of atypical features of MDD (MDD‐A) on the response to lithium augmentation (LA)
Hannah Buchbauer   +8 more
wiley   +1 more source

Emotional Responses (Intensity/Valence) Fulfill RDoC Criteria but Remain Excluded From Diagnostic Classifications of Mood Disorders

open access: yesBipolar Disorders, Volume 28, Issue 7, November 2026.
ABSTRACT Objectives Categorical classifications of depression, such as DSM‐5 and ICD, are limited by high clinical heterogeneity, arbitrary diagnostic thresholds, and weak links to underlying pathophysiology. In line with the Research Domain Criteria (RDoC) framework, this article proposes a dimensional and mechanistic approach centered on emotional ...
Chantal Henry   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy